Abstract
Superspreading events and overdispersion are hallmarks of the Covid-19 pandemic. To gain insight into the nature and controlling factors of these superspreading events and heterogeneity in transmission, we conducted mechanistic modeling of SARS-CoV-2 transmission by infectious aerosols using real-world occupancy data from a large number of full-service restaurants in ten US metropolises. Including a large number of factors that influence disease transmission in these settings, we demonstrate the emergence of a stretched tail in the probability density function of secondary infection numbers indicating strong heterogeneity in individual infectivity. Derived analytical results further demonstrate that variability in viral loads and variability in occupancy, together, lead to overdispersion in the number of secondary infections arising from individual index cases. Our analysis, connecting mechanistic understanding of SARS-CoV-2 transmission by aerosols with observed large-scale epidemiological characteristics of Covid-19 outbreaks, adds an important dimension to the mounting body of evidence with regards to the determinants of airborne transmission of SARS-CoV-2 by aerosols in indoor settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
UofT researchers acknowledge support from the Fields Institute for Research in Mathematical Sciences through their project Mathematics for Public Health and Variants of Concern sponsored by the Canadian Institutes of Health Research. SC acknowledges the Heuckroth Distinguished Faculty Award from UTIAS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not protected by agreements could be made available upon reasonable request to the corresponding author.
